BLCO
Bausch & Lomb Corp
Last earnings -2.4% on 2026-04-29
$16.35
▲ +2.77%$16.35▲ +39.39%
over 1Y
L $11.73EODHDH $18.60
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.8%
1W+9.3%
1M+3.8%
3M+6.2%
YTD-1.6%
1Y+39.1%
Hold
Conviction
Horizon
Long (>12mo)
Street · 18 analysts
Buy
Eye-care franchise growing revenue 6.5% with rising cash flow, but persistent net losses and $5B debt keep it speculative.
Bausch & Lomb is a global eye-health company (vision care, surgical, pharmaceuticals) with a recognizable franchise and steady top-line growth — FY2025 revenue rose 6.5% to $5.10B, the fourth straight year of growth from $3.77B in FY2021. The problem is that growth has not produced GAAP profit: the company posted a net loss of -$360M (worsening 13.6%) and an operating margin of just 2.2%, with operating income down 30.2% to $113M. Heavy depreciation/amortization ($421M, largely intangibles from its formation) and interest on $5.02B of debt overwhelm the modest operating profit.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $3.77B | $3.77B | $4.15B | $4.79B | $5.10B |
| Gross profit | — | — | — | — | — |
| Operating income | $329M | $207M | $130M | $162M | $113M |
| Net income | $182M | $6.00M | -$260M | -$317M | -$360M |
| Diluted EPS | $0.52 | $0.02 | -$0.74 | -$0.90 | -$1.02 |
| Net margin | 4.8% | 0.2% | -6.3% | -6.6% | -7.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$10.5B
EV / EBITDA19.6
EV / Sales2.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.2%
FCF yield-1.1%
Quality & risk
ROIC (est.)0.8%
Free cash flow-$66.0M
Total debt$5.05B
Net cash-$4.67B
Altman Z-Score0.85 distress
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-122026-06-16open ↗SDFiling2026-06-01open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-222026-05-26open ↗
Frequently asked
- Is Bausch & Lomb Corp (BLCO) a buy?
- BLCO currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Eye-care franchise growing revenue 6.5% with rising cash flow, but persistent net losses and $5B debt keep it speculative.
- What is Bausch & Lomb Corp's quality score?
- BLCO scores 52.68627450980392/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001860742, latest 10-Q filed 2026-04-29) · EODHD · analysis by claude-code · as of 6/21/2026, 8:58:17 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.